MONETTE: A Randomised Open-Label Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

Brief description of study

The purpose of the study is to evaluate the efficacy and safety/tolerability of ceralasertib, when administered alone and in combination with with durvalumab. We want to understand the mechanism of action for ceralasertib plus durvalumab and investigate ceralasertib as an immune modulator. The study drugs ceralasertib and durvalumab are investigational, which means that they have not been approved for melanoma by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.

Clinical Study Identifier: s21-00907 Identifier: NCT05061134
Principal Investigator: Jeffrey S. Weber.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.